Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Opexa Therapeutics (OPXA) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 6,360
  • Shares Outstanding, K 7,050
  • Annual Sales, $ 2,560 K
  • Annual Income, $ -12,020 K
  • 36-Month Beta 2.05
  • Price/Sales 2.40
  • Price/Book 1.40

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.50 +142.00%
on 11/15/16
1.49 -18.79%
on 11/21/16
+0.63 (+108.62%)
since 11/09/16
3-Month
0.50 +142.00%
on 11/15/16
4.38 -72.37%
on 10/07/16
-3.02 (-71.39%)
since 09/09/16
52-Week
0.50 +142.00%
on 11/15/16
4.93 -75.46%
on 08/24/16
-1.87 (-60.71%)
since 12/09/15

Most Recent Stories

More News
Opexa Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update

THE WOODLANDS, TX / ACCESSWIRE / November 14, 2016 / Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, today reported...

Opexa Announces Reduction in Workforce in Light of Top-Line Results from Phase 2b Abili-T Trial of Tcelna(R) (imilecleucel-T) in Secondary Progressive Multiple Sclerosis

THE WOODLANDS, TX / ACCESSWIRE / November 2, 2016 / Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS)...

Opexa Therapeutics Announces Phase 2b Abili-T Trial of Tcelna(R) (imilecleucel-T) in Secondary Progressive Multiple Sclerosis Did Not Meet Primary Endpoint

THE WOODLANDS, TX / ACCESSWIRE / October 28, 2016 / Opexa Therapeutics (Nasdaq: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, today announced that...

Opexa Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference

Final Patient Visit Completed in Phase 2b Clinical Trial of Tcelna (imilecleucel-T) in Secondary Progressive Multiple Sclerosis; Top-Line Results Expected in Early Q4 2016

Opexa Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference

Final Patient Visit Completed in Phase 2b Clinical Trial of Tcelna (imilecleucel-T) in Secondary Progressive Multiple Sclerosis; Top-Line Results Expected in Early Q4 2016

Opexa Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update

Abili-T Trial in Secondary Progressive MS On-Schedule With Top-Line Results Expected in Early Q4

Opexa Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update

Abili-T Trial in Secondary Progressive MS On-Schedule With Top-Line Results Expected in Early Q4

Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Second Quarter 2016 Financial Results

THE WOODLANDS, TX--(Marketwired - Aug 9, 2016) - Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS)...

Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Second Quarter 2016 Financial Results

THE WOODLANDS, TX--(Marketwired - Aug 9, 2016) - Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS)...

Opexa Therapeutics to Present at the 18th Annual BIO CEO and Investor Conference

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Opexa Therapeutics, Inc. develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin, a...

See More

Support & Resistance

2nd Resistance Point 1.77
1st Resistance Point 1.49
Last Price 1.21
1st Support Level 0.92
2nd Support Level 0.63

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.